\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\ is\\ unremarkable\\.\\ \ \(1\)\
\-\ labs\\:\ \(4\)\
\-\ hemoglobin\\/hematocrit\\:\\ 13\\.0\\/38\\.0\ \(0\)\
\-\ wbc\\:\\ 7\\.3\ \(0\)\
\-\ platelets\\:\\ 291\ \(0\)\
\-\ sodium\\:\\ 139\ \(0\)\
\-\ potassium\\:\\ 3\\.9\ \(0\)\
\-\ chloride\\:\\ 103\ \(0\)\
\-\ bicarbonate\\:\\ 25\\.7\ \(0\)\
\-\ glucose\\:\\ 103\ \(0\)\
\-\ creatinine\\:\\ 0\\.3\ \(0\)\
\-\ bun\\:\\ 16\ \(0\)\
\-\ c24\\:0\\ tetracosanoic\\ acid\\ \\(high\\)\\ 101\\.96\\ \ \(0\)\
\-\ \\\\-\\-reference\\ range\\:\\ 24\\.25\\ to\\ 77\\.75\\\\ unit\\:\\ umol\\/l\\ \ \(0\)\
\-\ c26\\:0\\ hexacocanoic\\ acid\\ \\(high\\)\\ 2\\.81\\\ \(0\)\
\-\ \\-reference\\ range\\:\\ 0\\.17\\ to\\ 0\\.73\\\\ unit\\:\\ umol\\/l\ \(0\)\
\-\ c24\\:0\\/c22\\:0\\ \\(high\\)\\ 1\\.86\\\\ \ \(0\)\
\-\ \\-\\ reference\\ range\\:\\ 0\\.64\\ to\\ 1\\.02\\ \ \(0\)\
\-\ c26\\:0\\/c22\\:0\\ \\(high\\)\\ 0\\.051\\\\ \ \(0\)\
\-\ \\-reference\\ range\\:\\ 0\\.003\\ to\\ 0\\.015\ \(0\)\
\-\ treatment\\:\\ current\\ treatment\\ modalities\\ include\\ dietary\\ therapy\\ involving\\ a\\ low\\-fat\\ diet\\ and\\ consumption\\ of\\ lorenzo\\â\\€\\™s\\ oil\\,\\ lovastatin\\ therapy\\,\\ bone\\ marrow\\ transplants\\,\\ and\\ iv\\ immunoglobulin\\ therapy\\.\ \(0\)\
\-\ follow\\ up\\:\\ genetic\\ counseling\\ for\\ family\ \(0\)\
\-\ head\\ ct\\ without\\ iv\\ contrast\\:\ \(0\)\
\-\ focal\\ low\\-attenuation\\ in\\ the\\ splenium\\Â\\ of\\Â\\ the\\Â\\ corpus\\Â\\ callosum\\,\\Â\\ with\\\\ associated\\Â\\ vasogenic\\Â\\ edema\\Â\\ extending\\Â\\ into\\Â\\ the\\Â\\ cerebral\\Â\\ white\\ matter\\ \\bilaterally\\.\\ lateral\\ ventricles\\ appear\\ borderline\\ enlarged\\,\\ r\\>l\ \(0\)\
\-\ head\\ mri\\ without\\ and\\ with\\ iv\\ contrast\\:\ \(0\)\
\-\ there\\Â\\ is\\Â\\ a\\ symmetric\\Â\\ and\\Â\\ confluent\\Â\\ signal\\Â\\ abnormality\\ involving\\Â\\ the\\Â\\ \\ splenium\\Â\\ of\\Â\\ the\\Â\\ corpus\\Â\\ callosum\\,\\Â\\ bilateral\\Â\\ peritrigonal\\ white\\Â\\ \\ matter\\,\\Â\\ and\\Â\\ corticospinal\\Â\\ tracts\\;\\ hyper\\-intense\\Â\\ on\\Â\\ t2\\-weighted\\ images\\Â\\ and\\Â\\ hypo\\-intense\\Â\\ on\\Â\\ t1\\ weighted\\Â\\ images\\.\\Â\\ \\ there\\Â\\ is\\Â\\ linear\\Â\\ peripheral\\Â\\ enhancment\\Â\\ just\\ beneath\\Â\\ the\\Â\\ leading\\Â\\ edge\\Â\\ of\\ the\\ abnormal\\ areas\\Â\\ including\\Â\\ the\\ peritrigonal\\Â\\ white\\Â\\ matter\\Â\\ and\\Â\\ corticospinal\\Â\\ tracts\\;\\Â\\ this\\Â\\ intermediatezone\\Â\\ enhancement\\Â\\ is\\Â\\ \\ typical\\Â\\ of\\ x\\-linked\\Â\\ adrenal\\ leukodystrophy\\.\\Â\\ mild\\ diffusion\\ restriction\\Â\\ \\ is\\Â\\ also\\Â\\ seen\\Â\\ in\\Â\\ an\\Â\\ identical\\ distribution\\ to\\ the\\ linear\\Â\\ enhancement\\,\\Â\\ \\ which\\Â\\ has\\Â\\ also\\Â\\ been\\Â\\ described\\Â\\ with\\Â\\ x\\-linked\\Â\\ ald\\Â\\ and\\ has\\Â\\ been\\Â\\ \\ attributed\\ to\\ active\\Â\\ demyelination\\.\\ on\\Â\\ t2\\-weighted\\Â\\ images\\,\\ this\\Â\\ thin\\Â\\ \\ intermediate\\ zone\\ is\\Â\\ about\\Â\\ iso\\-intense\\Â\\ to\\Â\\ normal\\Â\\ white\\ matter\\,\\ which\\Â\\ also\\Â\\ is\\ a\\ typical\\Â\\ finding\\.\\Â\\ no\\Â\\ abnormalities\\ are\\ identified\\ in\\Â\\ \\ the\\ frontal\\ white\\ matter\\.\\ the\\ ventricles\\Â\\ appear\\Â\\ normal\\ in\\Â\\ size\\Â\\ and\\ shape\\.\ \(0\)\
\-\ x\\-linked\\ adrenoleukodystrophy\ \(0\)\
\-\ leukoencephalopathy\ \(7\)\
\-\ leukodystrophy\ \(9\)\
\-\ this\\ is\\ a\\ 7\\ year\\ old\\ boy\\ who\\ presents\\ to\\ the\\ children\\'s\\ ed\\ with\\ dizziness\\,\\ ataxia\\,\\ weakness\\,\\ vomiting\\,\\ and\\ leg\\ twitching\\.\\ the\\ patient\\ had\\ been\\ at\\ a\\ wrestling\\ match\\ doing\\ warm\\ up\\ exercises\\ at\\ the\\ time\\ of\\ the\\ onset\\ of\\ symptoms\\.\\ \\ he\\ has\\ a\\ history\\ of\\ tics\\ and\\ nystagmus\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ \\:\\:\\ 0\\.06229861190499728\ \(0\)\
\-\ x\\-linked\\:\\ 0\\.05211254997346676\ \(0\)\
\-\ reference\\:\\ 0\\.048252081037169464\ \(0\)\
\-\ umol\\/l\\:\\ 0\\.046275687264916\ \(0\)\
\-\ peritrigonal\\:\\ 0\\.046275687264916\ \(0\)\
\-\ matter\\:\\ 0\\.04415328045145404\ \(0\)\
\-\ \\-\\-\\:\\ 0\\.041209126464511754\ \(0\)\
\-\ white\\:\\ 0\\.037192968670761384\ \(0\)\
\-\ corticospinal\\:\\ 0\\.036870125746658496\ \(0\)\
\-\ leukodystrophy\\:\\ 0\\.036870125746658496\ \(0\)\
\-\ range\\:\\ 0\\.03611800542028696\ \(0\)\
\-\ splenium\\:\\ 0\\.032422367949350335\ \(0\)\
\-\ 103\\:\\ 0\\.03140317627249492\ \(0\)\
\-\ tracts\\:\\ 0\\.030049742627864473\ \(0\)\
\-\ unit\\:\\ 0\\.027180746793911352\ \(0\)\
\-\ acid\\:\\ 0\\.026293207003654482\ \(0\)\
\-\ iv\\:\\ 0\\.024554527066622783\ \(0\)\
\-\ high\\:\\ 0\\.02455166468322116\ \(0\)\
\-\ 13\\.0\\/38\\.0\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 291\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 25\\.7\\:\\ 0\\.023137843632458\ \(0\)\
\-\ c24\\:0\\:\\ 0\\.023137843632458\ \(0\)\
\-\ tetracosanoic\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 101\\.96\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 24\\.25\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 77\\.75\\:\\ 0\\.023137843632458\ \(0\)\
\-\ c26\\:0\\:\\ 0\\.023137843632458\ \(0\)\
\-\ hexacocanoic\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 2\\.81\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 0\\.73\\:\\ 0\\.023137843632458\ \(0\)\
\-\ c24\\:0\\/c22\\:0\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 1\\.86\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 0\\.64\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 1\\.02\\:\\ 0\\.023137843632458\ \(0\)\
\-\ c26\\:0\\/c22\\:0\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 0\\.051\\:\\ 0\\.023137843632458\ \(0\)\
\-\ 0\\.015\\:\\ 0\\.023137843632458\ \(0\)\
\-\ low\\-fat\\:\\ 0\\.023137843632458\ \(0\)\
\-\ lorenzo\\:\\ 0\\.023137843632458\ \(0\)\
\-\ lovastatin\\:\\ 0\\.023137843632458\ \(0\)\
\-\ intermediatezone\\:\\ 0\\.023137843632458\ \(0\)\
\-\ ald\\:\\ 0\\.023137843632458\ \(0\)\
\-\ tics\\:\\ 0\\.023137843632458\ \(0\)\
\-\ callosum\\:\\ 0\\.02301680643109283\ \(0\)\
\-\ t2\\-weighted\\:\\ 0\\.02271329162327747\ \(0\)\
\-\ corpus\\:\\ 0\\.022101565553692422\ \(0\)\
\-\ 0\\.17\\:\\ 0\\.021318559693980454\ \(0\)\
\-\ 0\\.003\\:\\ 0\\.021318559693980454\ \(0\)\
\-\ hypo\\-intense\\:\\ 0\\.021318559693980454\ \(0\)\
\-\ ventricles\\:\\ 0\\.021100933744723133\ \(0\)\
\-\ hemoglobin\\/hematocrit\\:\\ 0\\.020254346811806795\ \(0\)\
\-\ adrenoleukodystrophy\\:\\ 0\\.020254346811806795\ \(0\)\
\-\ linear\\:\\ 0\\.019016071249744294\ \(0\)\
\-\ bicarbonate\\:\\ 0\\.01891359714312965\ \(0\)\
\-\ hyper\\-intense\\:\\ 0\\.01891359714312965\ \(0\)\
\-\ iso\\-intense\\:\\ 0\\.018435062873329248\ \(0\)\
\-\ appear\\:\\ 0\\.01835904687728232\ \(0\)\
\-\ been\\:\\ 0\\.018305471570582606\ \(0\)\
\-\ twitching\\:\\ 0\\.018030467913152715\ \(0\)\
\-\ wrestling\\:\\ 0\\.018030467913152715\ \(0\)\
\-\ match\\:\\ 0\\.018030467913152715\ \(0\)\
\-\ therapy\\:\\ 0\\.017989297608193802\ \(0\)\
\-\ typical\\:\\ 0\\.017986596819685025\ \(0\)\
\-\ 139\\:\\ 0\\.01767999181702536\ \(0\)\
\-\ transplants\\:\\ 0\\.01767999181702536\ \(0\)\
\-\ enhancment\\:\\ 0\\.01767999181702536\ \(0\)\
\-\ consumption\\:\\ 0\\.017370849991155585\ \(0\)\
\-\ low\\-attenuation\\:\\ 0\\.017370849991155585\ \(0\)\
\-\ 7\\.3\\:\\ 0\\.017094313204652104\ \(0\)\
\-\ immunoglobulin\\:\\ 0\\.017094313204652104\ \(0\)\
\-\ chloride\\:\\ 0\\.01640569308793953\ \(0\)\
\-\ 0\\.3\\:\\ 0\\.01640569308793953\ \(0\)\
\-\ oil\\:\\ 0\\.016211183974675168\ \(0\)\
\-\ 3\\.9\\:\\ 0\\.016030100322478445\ \(0\)\
\-\ beneath\\:\\ 0\\.016030100322478445\ \(0\)\
\-\ counseling\\:\\ 0\\.015860707878547813\ \(0\)\
\-\ involving\\:\\ 0\\.015739670677182644\ \(0\)\
\-\ potassium\\:\\ 0\\.01570158813624746\ \(0\)\
\-\ leukoencephalopathy\\:\\ 0\\.015551566052678042\ \(0\)\
\-\ identical\\:\\ 0\\.015409657335433223\ \(0\)\
\-\ restriction\\:\\ 0\\.015146971092501509\ \(0\)\
\-\ dietary\\:\\ 0\\.015024871313932237\ \(0\)\
\-\ sodium\\:\\ 0\\.014908200021095403\ \(0\)\
\-\ demyelination\\:\\ 0\\.014908200021095403\ \(0\)\
\-\ borderline\\:\\ 0\\.014796494996374152\ \(0\)\
\-\ confluent\\:\\ 0\\.014796494996374152\ \(0\)\
\-\ platelets\\:\\ 0\\.014586409149461983\ \(0\)\
\-\ warm\\:\\ 0\\.014299796834593238\ \(0\)\
\-\ attributed\\:\\ 0\\.014210816384000898\ \(0\)\
\-\ nystagmus\\:\\ 0\\.014124753856906435\ \(0\)\
\-\ exercises\\:\\ 0\\.013960658431758576\ \(0\)\
\-\ diet\\:\\ 0\\.013732282114200495\ \(0\)\
\-\ modalities\\:\\ 0\\.013455745327697012\ \(0\)\
\-\ doing\\:\\ 0\\.013327687154023962\ \(0\)\
\-\ also\\:\\ 0\\.013264721210001192\ \(0\)\
\-\ intermediate\\:\\ 0\\.012923092193847432\ \(0\)\
\-\ images\\:\\ 0\\.012907589700388614\ \(0\)\
\-\ creatinine\\:\\ 0\\.012767125210984437\ \(0\)\
\-\ head\\:\\ 0\\.012722316590939087\ \(0\)\
\-\ has\\:\\ 0\\.012635432838537622\ \(0\)\
\-\ edge\\:\\ 0\\.012572616097720075\ \(0\)\
\-\ bun\\:\\ 0\\.012391532445523355\ \(0\)\
\-\ genetic\\:\\ 0\\.012263474271850304\ \(0\)\
\-\ vasogenic\\:\\ 0\\.012141374493281029\ \(0\)\
\-\ up\\:\\ 0\\.012062189769313508\ \(0\)\
\-\ dizziness\\:\\ 0\\.012024703200444195\ \(0\)\
\-\ enhancement\\:\\ 0\\.012023563076761343\ \(0\)\
\-\ glucose\\:\\ 0\\.011986937485346821\ \(0\)\
\-\ ataxia\\:\\ 0\\.011986937485346821\ \(0\)\
\-\ zone\\:\\ 0\\.011912998175722948\ \(0\)\
\-\ is\\:\\ 0\\.01180663051726458\ \(0\)\
\-\ shape\\:\\ 0\\.011669476565615424\ \(0\)\
\-\ adrenal\\:\\ 0\\.011356645811638736\ \(0\)\
\-\ leading\\:\\ 0\\.010730001588593588\ \(0\)\
\-\ \\;\\:\\ 0\\.010632132222848261\ \(0\)\
\-\ without\\:\\ 0\\.010561748904767245\ \(0\)\
\-\ current\\:\\ 0\\.01050743850024693\ \(0\)\
\-\ symmetric\\:\\ 0\\.010243736320814819\ \(0\)\
\-\ l\\:\\ 0\\.010224507869129588\ \(0\)\
\-\ r\\:\\ 0\\.010186468479884006\ \(0\)\
\-\ 16\\:\\ 0\\.010148972529103227\ \(0\)\
\-\ distribution\\:\\ 0\\.0100937142372454\ \(0\)\
\-\ contrast\\:\\ 0\\.010040817253584805\ \(0\)\
\-\ diffusion\\:\\ 0\\.010039595373196226\ \(0\)\
\-\ \\,\\:\\ 0\\.009947351488824209\ \(0\)\
\-\ marrow\\:\\ 0\\.009866857266714409\ \(0\)\
\-\ weighted\\:\\ 0\\.009752367443943043\ \(0\)\
\-\ children\\:\\ 0\\.009689119277068869\ \(0\)\
\-\ described\\:\\ 0\\.009552148796306217\ \(0\)\
\-\ ed\\:\\ 0\\.0094790334301567\ \(0\)\
\-\ just\\:\\ 0\\.009366126907627328\ \(0\)\
\-\ thin\\:\\ 0\\.009218408178234706\ \(0\)\
\-\ family\\:\\ 0\\.009192421115287954\ \(0\)\
\-\ treatment\\:\\ 0\\.009079354118639827\ \(0\)\
\-\ to\\:\\ 0\\.008967309363632258\ \(0\)\
\-\ leg\\:\\ 0\\.00881941550815957\ \(0\)\
\-\ about\\:\\ 0\\.008645820225995412\ \(0\)\
\-\ 7\\:\\ 0\\.008593844826267906\ \(0\)\
\-\ active\\:\\ 0\\.008563146559172915\ \(0\)\
\-\ vomiting\\:\\ 0\\.008563146559172915\ \(0\)\
\-\ which\\:\\ 0\\.008373462400223353\ \(0\)\
\-\ weakness\\:\\ 0\\.00832968859062568\ \(0\)\
\-\ abnormality\\:\\ 0\\.008274430298767853\ \(0\)\
\-\ abnormalities\\:\\ 0\\.008238227353538626\ \(0\)\
\-\ wbc\\:\\ 0\\.008176049476576934\ \(0\)\
\-\ peripheral\\:\\ 0\\.0081153105564675\ \(0\)\
\-\ including\\:\\ 0\\.008098211656149407\ \(0\)\
\-\ identified\\:\\ 0\\.00801434918946541\ \(0\)\
\-\ labs\\:\\ 0\\.007800456711115848\ \(0\)\
\-\ cerebral\\:\\ 0\\.007770200792031682\ \(0\)\
\-\ enlarged\\:\\ 0\\.007652548741165371\ \(0\)\
\-\ boy\\:\\ 0\\.007623941679595725\ \(0\)\
\-\ \\(\\:\\ 0\\.007583850144292499\ \(0\)\
\-\ this\\:\\ 0\\.007568009553654591\ \(0\)\
\-\ areas\\:\\ 0\\.007546842969149781\ \(0\)\
\-\ extending\\:\\ 0\\.0075399450100782075\ \(0\)\
\-\ size\\:\\ 0\\.007519359242463967\ \(0\)\
\-\ \\)\\:\\ 0\\.007491209366018951\ \(0\)\
\-\ \\>\\:\\ 0\\.007451883240599907\ \(0\)\
\-\ unremarkable\\:\\ 0\\.007425371177643204\ \(0\)\
\-\ bilaterally\\:\\ 0\\.007366680416073237\ \(0\)\
\-\ finding\\:\\ 0\\.007228507887240108\ \(0\)\
\-\ follow\\:\\ 0\\.007126507800384341\ \(0\)\
\-\ t1\\:\\ 0\\.007108912168567569\ \(0\)\
\-\ onset\\:\\ 0\\.007079845737336351\ \(0\)\
\-\ frontal\\:\\ 0\\.007045385654811961\ \(0\)\
\-\ normal\\:\\ 0\\.007032086375848299\ \(0\)\
\-\ \\â\\€\\™\\:\\ 0\\.006703482256287286\ \(0\)\
\-\ there\\:\\ 0\\.0066756722124146385\ \(0\)\
\-\ s\\:\\ 0\\.0064324610685422235\ \(0\)\
\-\ focal\\:\\ 0\\.0064054950239853066\ \(0\)\
\-\ abnormal\\:\\ 0\\.006396567559881657\ \(0\)\
\-\ edema\\:\\ 0\\.006343631205856406\ \(0\)\
\-\ time\\:\\ 0\\.006334911357583498\ \(0\)\
\-\ include\\:\\ 0\\.006291741438399703\ \(0\)\
\-\ he\\:\\ 0\\.006257709559141783\ \(0\)\
\-\ a\\:\\ 0\\.006245666170371674\ \(0\)\
\-\ at\\:\\ 0\\.006077496865257916\ \(0\)\
\-\ signal\\:\\ 0\\.0059135809193511255\ \(0\)\
\-\ mild\\:\\ 0\\.00590617704443868\ \(0\)\
\-\ who\\:\\ 0\\.005847686113232813\ \(0\)\
\-\ on\\:\\ 0\\.005699929231223843\ \(0\)\
\-\ symptoms\\:\\ 0\\.005589652170336323\ \(0\)\
\-\ bone\\:\\ 0\\.005573319373910419\ \(0\)\
\-\ physical\\:\\ 0\\.005502638502837895\ \(0\)\
\-\ bilateral\\:\\ 0\\.0054430911530562835\ \(0\)\
\-\ the\\:\\ 0\\.005442885224552197\ \(0\)\
\-\ into\\:\\ 0\\.005336814614067472\ \(0\)\
\-\ associated\\:\\ 0\\.005292552655925727\ \(0\)\
\-\ and\\:\\ 0\\.005197110401717593\ \(0\)\
\-\ mri\\:\\ 0\\.005152954999775905\ \(0\)\
\-\ \\'s\\:\\ 0\\.004945004247682533\ \(0\)\
\-\ exam\\:\\ 0\\.004927123201967291\ \(0\)\
\-\ lateral\\:\\ 0\\.004846897757544751\ \(0\)\
\-\ had\\:\\ 0\\.004839500837902121\ \(0\)\
\-\ presents\\:\\ 0\\.0045817435577635846\ \(0\)\
\-\ seen\\:\\ 0\\.004432093477867953\ \(0\)\
\-\ in\\:\\ 0\\.00442411790173496\ \(0\)\
\-\ ct\\:\\ 0\\.0031372799301628423\ \(0\)\
\-\ an\\:\\ 0\\.0031014825834244876\ \(0\)\
\-\ history\\:\\ 0\\.0030976759519870953\ \(0\)\
\-\ are\\:\\ 0\\.003057411738922839\ \(0\)\
\-\ year\\:\\ 0\\.002509462649010275\ \(0\)\
\-\ of\\:\\ 0\\.002446274032503694\ \(0\)\
\-\ old\\:\\ 0\\.002296416264730327\ \(0\)\
\-\ no\\:\\ 0\\.0022583835976477742\ \(0\)\
\-\ patient\\:\\ 0\\.002248272784557449\ \(0\)\
\-\ for\\:\\ 0\\.0019136696814769426\ \(0\)\
\-\ with\\:\\ 0\\.0012283903001563228\ \(0\)\
\-\ \\.\\:\\ 0\\.0010249209896871629\ \(0\)\
